UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 4, 2022
ACER THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-33004 | | 32-0426967 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
One Gateway Center, Suite 351
300 Washington Street Newton, Massachusetts | | 02458 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (844) 902-6100 |
N/A |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | |
Securities registered pursuant to Section 12(b) of the Act: |
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
Common Stock, $0.0001 par value per share | ACER | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01.Other Events
On April 4, 2022, Acer Therapeutics Inc. (the “Company”) raised aggregate gross proceeds, before deducting fees and offering costs, of approximately $3.2 million under its existing “at-the-market” offering program. The Company sold an aggregate of 1,000,000 shares at an average gross sale price of $3.1746 per share. Aggregate net proceeds were approximately $3.1 million after fees and offering costs of $0.1 million. The sales were made by JonesTrading Institutional Services LLC pursuant to the Amended and Restated Sales Agreement (the “Sales Agreement”) dated March 18, 2020 between the Company, on the one hand, and JonesTrading Institutional Services LLC and Roth Capital Partners, LLC as sales agents, on the other hand.
The shares sold under the Sales Agreement were pursuant to a shelf registration statement on Form S-3 (File No. 333‑261342) previously filed by the Company and declared effective by the Securities and Exchange Commission (“SEC”) on December 7, 2021. A prospectus supplement related to the Company’s at-the-market offering program was also filed with the SEC on December 14, 2021.
As of April 6, 2022 and after the sales described above, the Company has 15,310,244 shares of common stock outstanding.
This Current Report on Form 8-K does not constitute an offer to sell nor the solicitation of an offer to buy shares of the Company’s common stock, nor shall there be any sale of shares of the Company’s common stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: April 6, 2022 | ACER THERAPEUTICS INC. | |
| | | |
| By: | /s/ Harry S. Palmin | |
| | Harry S. Palmin | |
| | Chief Operating Officer and Chief Financial Officer | |
3
